分析绝经后骨质疏松症应用阿仑膦酸钠与激素替代疗法的治疗效果

目的分析绝经后骨质疏松症应用阿仑膦酸钠与激素替代疗法治疗的临床效果。方法70例绝经后骨质疏松症患者作为研究对象,依据随机数字表法分为对照组与观察组,每组35例。对照组患者口服替勃龙治疗,观察组患者口服阿仑膦酸钠治疗。比较两组患者骨密度、临床疗效与雌二醇(E2)、促卵泡生成素(FSH)水平。结果治疗前,对照组患者的腰椎1-4骨密度为(0.820±0.020)g/cm^2,右侧股骨颈骨密度为(0.746±0.019)g/cm^2;观察组的腰椎1-4骨密度为(0.821±0.020)g/cm^2,右侧股骨颈骨密度为(0.745±0.021)g/cm^2。治疗后,对照组的腰椎1-4骨密度为(0.851±0.018)g/cm^2,右侧股骨颈骨密度为(0.764±0.022)g/cm^2;观察组的腰椎1-4骨密度为(0.856±0.014)g/cm^2、右侧股骨颈骨密度为(0.762±0.018)g/cm^2。治疗后,两组患者腰椎1-4及右侧股骨颈骨密度均优于本组治疗前,差异具有统计学意义(P<0.05)。治疗后,两组患者腰椎1-4及右侧股骨颈的骨密度比较,差异无统计学意义(P>0.05)。观察组治疗总有效率为100%,与对照组的100%比较,差异无统计学意义(P>0.05)。治疗前,对照组患者E2水平为(32.04±25.08)pg/ml,FSH水平为(72.54±32.08)mIU/ml;观察组患者E2水平为(33.54±29.10)pg/ml,FSH水平为(69.09±27.08)mIU/ml。治疗前,两组患者E2及FSH水平比较,差异无统计学意义(P>0.05)。治疗后,对照组患者E2水平为(64.32±28.54)pg/ml,FSH水平为(45.08±25.27)mIU/ml;观察组患者E2水平为(33.62±22.08)pg/ml,FSH水平为(71.04±22.42)mIU/ml。治疗后,对照组患者E2水平高于本组治疗前,FSH水平低于本组治疗前,差异具有统计学意义(P<0.05)。治疗后,观察组患者E2及FSH水平与本组治疗前比较,差异无统计学意义(P>0.05)。结论阿仑膦酸钠与激素代替疗法均能有效提高绝经后骨质疏松症患者的骨密度,但是与激素代替疗法相比,阿仑膦酸钠对患者的血清E2、FSH水平影响较小。

Analysis of the effect of alendronate sodium and hormone replacement therapy on postmenopausal osteoporosis

Objective To analyze the clinical effect of alendronate sodium and hormone replacement therapy on postmenopausal osteoporosis.Methods A total of 70 patients with postmenopausal osteoporosis as study subjects were randomly divided into control group and observation group,with 35 cases in each group.The control group was treated with tibolone orally,while the observation group was treated with alendronate sodium orally.The bone mineral density,clinical efficacy,estradiol(E2),follicle stimulating hormone(FSH)levels were compared between the two groups.Results Before treatment,the bone density of the lumbar spine 1-4 and the bone density of the right femoral neck of the control group were(0.820±0.020)and(0.746±0.019)g/cm^2,which were(0.821±0.020)and(0.745±0.021)g/cm^2 of the observation group.After treatment,the bone density of the lumbar spine 1-4 and the bone density of the right femoral neck of the control group were(0.851±0.018)and(0.764±0.022)g/cm^2,which were(0.856±0.014)and(0.762±0.018)g/cm^2 of the observation group.After treatment,the bone density of the lumbar spine 1-4 and right femoral neck of the two groups were better than those before treatment,and the difference was statistically significant(P<0.05).After treatment,there was no statistically significant difference in bone density of the lumbar spine 1-4 and right femoral neck between the two groups(P>0.05).The total effective rate of treatment of the observation group was 100%,which had no statistically significant difference compared with 100%of the control group(P>0.05).Before treatment,E2 and FSH of the control group were(32.04±25.08)pg/ml,and(72.54±32.08)mIU/ml,which were(33.54±29.10)pg/ml and(69.09±27.08)mIU/ml of the observation group.After treatment,E2 and FSH of the control group were(64.32±28.54)pg/ml and(45.08±25.27)mIU/ml,which were(33.62±22.08)pg/ml and(71.04±22.42)mIU/ml of the observation group.After treatment,E2 of the control group was higher that that before treatment,and FSH was lower than that before treatment,and the difference was statistically significant(P<0.05).After treatment,E2 and FSH of the observation group had no statistically significant difference compared with those before treatment(P>0.05).Conclusion Both alendronate and hormone replacement therapy can effectively increase the bone mineral density of patients with postmenopausal osteoporosis,but compared with hormone replacement therapy,alendronate has less effect on patients’serum E2 and FSH levels.